Single-port Robotic Radical Gastrectomy for Gastric Cancer

Daping Hospital and the Research Institute of Surgery of the Third Military Medical University

Chuan Huang

H pylori positive individual receiving triple therapy

Rabeprazole Sodium, Amoxicillin Hydrate, Clarithromycin

Endoscopic examinations were conducted using a GIF-150 endoscope in combination with the CV150 system (Olympus Co., Tokyo, Japan).

Upper gastrointestinal endoscopy for the H. pylori and serum pepsinogen positive individuals (high risk group of gastric cancer)

The H pylori positive individuals are treated by triple therapy. After 6-8 weeks, the eradication is confirmed by using the UBT (13C Urea Breath Test: Beijing Richen-force Science \& Technology Co. Ltd).

After eradication of the H pylori with drug success of the therapy was assessed 6 to 8 weeks after treatment using the UBT(C13 Urea Breath Test: Beijing Richen-Force Science \& Techinology Co. Ltd.)

Urea Breath Test for the prevalence of H pylori

대만 원주민의 위암 예방을 위한 건강 불평등 원인 분석과 예방 전략 수립을 목표로 한 개입 연구입니다.

13C-urea breath test and anti-H. pylori treatment for those who are tested positive.

Participants will receive the 13C-urea breath test and those with test positive will further receive H. pylori eradication treatment.

Gastric cancer prevention

Screening program is audited by the standardized quality indicators, including the participation rate, the positivity rate, the referral-to-treatment rate, and the eradication rate .

Execution of the program

Our short-term outcome is the acceptability and feasibility of this screening program, which will be evaluated by answering whether the screening quality indicators can reach the minimal requirements.

13C 요소 호흡 검사 및 양성 판정을 받은 사람에 대한 헬리코박터 파일로리균 치료.

위암 예방

프로그램 실행

우리의 단기적인 성과는 이 선별 검사 프로그램의 수용 가능성과 실현 가능성을 평가하는 것이며, 이는 선별 검사 품질 지표가 최소 요구 사항을 충족하는지 여부를 통해 평가될 것입니다.

Yi-Chia Lee, MD, PhD

원주민을 위한 위암 예방

Participants in this arm will receive guideline-recommended systemic treatment according to their disease stage, including neoadjuvant or conversion therapy, adjuvant chemotherapy, or systemic therapy for advanced disease. Plasma circulating tumor DNA (ctDNA) will be collected at predefined time points during treatment. Treatment decisions, including continuation or adjustment of therapy in selected phases, will be guided by predefined ctDNA molecular response criteria within standard-of-care options. No investigational drugs will be used.

Plasma circulating tumor DNA (ctDNA) will be analyzed using a targeted next-generation sequencing panel to assess tumor-specific genetic alterations. Blood samples will be collected at predefined time points during treatment. ctDNA dynamics, including clearance or changes in mutation allele frequency, will be used to evaluate molecular response and guide treatment decisions within standard-of-care options.

Circulating Tumor DNA (ctDNA) Analysis

Participants will receive guideline-recommended systemic treatment according to disease stage and clinical practice, including neoadjuvant or conversion therapy, adjuvant chemotherapy, or systemic therapy for advanced disease. Treatment regimens may include fluoropyrimidine- and platinum-based chemotherapy, with or without PD-1 inhibitors or other standard agents. All treatments are administered according to standard-of-care and are not investigational.

Standard Systemic Therapy for Gastric Cancer

Weijian Guo

Medical images and clinical data related to gastric cancer were prospectively collected using a Philips Quark CT scanner, and its diagnostic accuracy and clinical application value in gastric cancer patients with different MSI statuses were evaluated to achieve accurate staging of gastric cancer. Patients diagnosed with gastric cancer at Yunnan Cancer Hospital from August 2025 to December 2026 were consecutively enrolled. After undergoing Philips Quark CT scanning, the N stage of gastric cancer was independently assessed by two radiologists, and statistical analysis was subsequently performed for the final results.

Abdominal CT scans were performed in addition to conventional treatment regimens

위암에 대한 단일 포트 로봇 근치적 위절제술

라베프라졸 나트륨, 아목시실린 수화물, 클라리스로마이신, 헬리코박터 파일로리 및 혈청 펩시노겐 양성자(위암 고위험군)를 위한 상부 위장관 내시경 검사, 헬리코박터 파일로리 유병률에 대한 요소 호흡 검사

원주민을 위한 위암 예방

순환 종양 DNA(ctDNA) 분석, 위암의 표준 전신 치료

다양한 MSI 상태를 가진 위암의 진단 및 치료에서 스펙트럼 CT의 가치를 탐구합니다.